Akeso Biopharma’s Ivonescimab NDA Accepted by NMPA, Strengthening NSCLC Treatment Options
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has received a significant boost...
PD-1/L1
AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines
AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second...
Junshi Biosciences’ Loqtorzi Inches Closer to Expanded Indication with NMPA Filing Acceptance
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has taken a significant step forward...
Shanghai Fosun Pharmaceutical Gets NMPA Green Light for FH-2001 and Serplulimab Combo Clinical Trial
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a prominent pharmaceutical company in...
Roche’s Tiragolumab Misses Primary Endpoints in NSCLC Trial, Study Halted
Roche (SWX: ROG; SWX: RO; OTCMKTS: RHHBY), the Swiss pharmaceutical giant, has announced that a...
Shanghai Henlius Biotech Advances Serplulimab Phase III Trial for First-Line Metastatic Colorectal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...
Tracon Pharmaceuticals Halts Development of Envafolimab After Clinical Trial Failure
Tracon Pharmaceuticals (OTCMKTS: TCON), a US-based biopharmaceutical company, has decided to cease development of its...
BeiGene’s Tislelizumab Approved by China’s NMPA for First-Line Extensive Stage Small Cell Lung Cancer
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a biopharmaceutical company, has announced that its programmed-death...
CSPC Pharmaceutical’s Enronsubaimab Gets NMPA Nod for Recurrent Cervical Cancer
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Nod for First-Line TNBC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...
MSD’s Keytruda Secures FDA Approval for Advanced or Recurrent Endometrial Carcinoma
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...
Junshi Biosciences’ Toripalimab Scores New Indication for First-Line ES-SCLC Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced an expansion of indications...
Junshi Biosciences’ Toripalimab-Bevacizumab Combo Meets Primary Endpoints in HCC Phase III Trial
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has declared a significant milestone with...
Gilead and Arcus Biosciences Report Positive Combination Therapy Results in mCRC Trial
Biopharmaceutical companies Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced safety and efficacy...
Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns
FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...
Gilead and Arcus Biosciences Report Positive Interim Phase II Data for Domvanalimab Combo in GI Cancers
Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced interim Phase II data for...
Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors
Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical...
CStone Pharmaceuticals’ Sugemalimab Receives Positive CHMP Opinion for NSCLC Treatment in Europe
CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced that it has...
Akeso Inc.’s Ivonescimab Shows Positive Interim Analysis in Phase III NSCLC Study
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced positive interim analysis...
Alphamab Oncology’s KN046 Misses Primary Endpoint in Phase III Pancreatic Cancer Study
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has announced disappointing results from...